The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Open accessAbstract
Autologous T cells genetically modified to express a chimeric antibody receptor (CAR) against carboxy-anhydrase-IX (CAIX) were administered to 12 patients with CAIX-expressing metastatic renal cell carcinoma (RCC). Patients were treated in three cohorts with a maximum of 10 infusions of a total of 0.2 to 2.1 × 10(9) CAR T cells. CTC grade 2-4 liver enzyme disturbances occurred at the lowest CAR T cell doses, necessitating cessation of treatment in four out of eight patients in cohorts 1 and 2. Examination of liver biopsies revealed CAIX expression on bile duct epithelium with infiltration of T cells, including CAR T cells. Subsequently four patients were pre-treated with CAIX monoclonal antibody (mAb) G250 to prevent CAR-specific toxicity and showed no liver toxicities and indications for enhanced peripheral T cell persistence. No clinical responses were recorded. This report shows that CAIX-targeting CAR T cells exerted antigen-specific effects in vivo and induced liver toxicity at the lowest dose of 0.2 × 10(9) T cells applied, illustrating the potency of receptor-modified T cells. We provide in-patient proof that the observed "on-target" toxicity is antigen-directed and can be prevented by blocking antigenic sites in off-tumor organs and allowing higher T cell doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Self-citationTill, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J., Powell, D. J., & Rosenberg, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7125 · Cited by 463
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Self-citationPastorekova, S., Parkkila, S., Parkkila, A., Opavsky, R., Zelnik, V, Saarnio, J., & Pastorek, J. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024293 · Cited by 351
Yang, B., O'Herrin, S. M., Wu, J., Reagan-Shaw, S., Ma, Y., Bhat, K. M. R., Gravekamp, C., Setaluri, V., Peters, N., Hoffmann, F. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1478 · Cited by 272
Savoldo, B., Goss, J. A., Hammer, M. M., Zhang, L., Lopez, T., Gee, A. P., Lin, Y.-F., Quiros-Tejeira, R. E., Reinke, P., Schubert, S., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021782 · Cited by 268
Huang, J., Khong, H. T., Dudley, M. E., El-Gamil, M., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000158855.92792.7a · Cited by 194
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Di Re, E. M., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187
Self-citationCAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe
Gilham, D. E., Debets, R., Pule, M., Hawkins, R. E., & Abken, H. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.009 · Cited by 179
Self-citationA phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
Bleumer, I., Knuth, A., Oosterwijk, E., Hofmann, R., Varga, Z., Lamers, C., Kruit, W., Melchior, S., Mala, C., Ullrich, S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601617 · Cited by 173
Self-citationKuo, W.-Y., Lin, J.-Y., & Tang, T. K. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q · Cited by 147
Davis, J. L., Theoret, M. R., Zheng, Z., Lamers, C. H. J., Rosenberg, S. A., & Morgan, R. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1280 · Cited by 132
Self-citationTreatment selection in metastatic renal cell carcinoma: expert consensus
Escudier, B. J., Szczylik, C. A., Porta, C., & Gore, M. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.59 · Cited by 128
Lucas, S., Plaen, E. D., & Boon, T. (2000) · International Journal of Cancer · Cited by 122
Alter, E. L. A. W., Hilip, P., Reenberg, D. G., Ilbert, M. A. J. G., Inch, R. O. J. F., Atanabe, S. W., Onnall, E. D., Homas, T., & Iddell, S. T. R. R. (2011) · Cited by 117
Steffens, M. G., Boerman, O. C., de Mulder, P. H., Oyen, W. J. G., Buijs, W. C. A. M., Witjes, J. A., van den Broek, W. J. A. A., Oosterwijk‐Wakka, J. C., Debruyne, F. M. J., Corstens, F. H. M., et al. (1999) · PubMed · Cited by 113
Self-citationEstablishment of Antitumor Memory in Humans Using in Vitro–Educated CD8 + T Cells
Butler, M. O., Friedlander, P. A., Milstein, M. I., Mooney, M. M., Metzler, G., Murray, A. P., Tanaka, M., Berezovskaya, A., Imataki, O., Drury, L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002207 · Cited by 107
Divgi, C. R., O’Donoghue, J. A., Welt, S., O'Neel, J., Finn, R., Motzer, R. J., Jungbluth, A. A., Hoffman, E. W., Ritter, G., Larson, S. M., et al. (2004) · PubMed · Cited by 103
Lucas, S., Plaen, E. D., & Boon, T. (2000) · International Journal of Cancer · Cited by 96
Lamers, C. H. J., Langeveld, S. C. L., Ruijven, C. M. G.-V., Debets, R., Sleijfer, S., & Gratama, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0330-3 · Cited by 94
Self-citationBrouwers, A. H., Mulders, P., Mulder, P. H. M. D., van den Broek, W. J. M., Buijs, W. C. A. M., Mala, C., Joosten, F. B. M., Oosterwijk, E., Boerman, O. C., Corstens, F. H. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.732 · Cited by 82
Self-citationDevelopment of Adoptive Cell Therapy for Cancer: A Clinical Perspective
Hawkins, R. E., Gilham, D. E., Debets, R., Eshhar, Z., Taylor, N. N., Abken, H., Schumacher, T. N., & ATTACK Consortium (2010) · Human Gene Therapy · doi:10.1089/hum.2010.086 · Cited by 79
Self-citationLamers, C. H. J., Willemsen, R. A., Luider, B. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700477 · Cited by 73
Self-citationT-cell therapy at the threshold
June, C. H., Rosenberg, S. A., Sadelain, M., & Weber, J. S. (2012) · Nature Biotechnology · doi:10.1038/nbt.2305 · Cited by 59
Steffens, M. G., Boerman, O. C., Oyen, W. J. G., et al. (1999) · PubMed · Cited by 45
TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
Straetemans, T., van Brakel, M., van Steenbergen, S. C. L., Broertjes, M., Drexhage, J., Hegmans, J. P., Lambrecht, B. N., Lamers, C., van der Bruggen, P., Coulie, P. G., et al. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/586314 · Cited by 42
Self-citationBrouwers, A. H., Buijs, W. C. A. M., Mulders, P., Mulder, P. H. M. D., van den Broek, W. J. M., Mala, C., Oosterwijk, E., Boerman, O. C., Corstens, F. H. M., & Oyen, W. J. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0010 · Cited by 42
Self-citationLamers, C. H. J., Gratama, J. W., Pouw, N. M. C., Langeveld, S. C. L., Krimpen, B. A. V., Kraan, J., Stoter, G., & Debets, R. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1452 · Cited by 40
Self-citationT cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies
Coccoris, M., Straetemans, T., Govers, C., Lamers, C., Sleijfer, S., & Debets, R. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003614756 · Cited by 40
Self-citationLamers, C. H. J., van Elzakker, P., Langeveld, S. C. L., Sleijfer, S., & Gratama, J. W. (2006) · Cytotherapy · doi:10.1080/14653240601056396 · Cited by 36
Self-citationRetroviral vectors for clinical immunogene therapy are stable for up to 9 years
Lamers, C. H. J., van Elzakker, P., Luider, B. A., van Steenbergen, S. C. L., Sleijfer, S., Debets, R., & Gratama, J. W. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701114 · Cited by 16
Self-citationStraetemans, T., Coccoris, M., Berrevoets, C., Treffers-Westerlaken, E., Scholten, C. E. V., Schipper, D., ten Hagen, T. L. M., & Debets, R. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.126 · Cited by 12
Self-citation
Cited by
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Metadata
- Authors
- Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., & Gratama, J. W.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 21
- Issue
- 4
- Pages
- 904-912
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2007753570
- Cited by
- 704
- References
- 46
- FWCI
- 22.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.